Introduction {#S0001}
============

Macroautophagy/autophagy is a biochemical process necessary for the maintenance of intracellular homeostasis, and its failure can lead to pathological problems such as metabolic diseases, tumors, and developmental defects. Considering that interfering with autophagy is a potential therapy for several diseases, autophagy has become a promising and attractive target for the pharmaceutical industry \[[1](#CIT0001),[2](#CIT0002)\]. However, the regulatory mechanisms and pathophysiological states of autophagy have not been fully elucidated, especially for tumors \[[2](#CIT0002),[3](#CIT0003)\]. Estrogen is a sex hormone that plays an important role not only in the development of female secondary sexual characteristics, but also in bone development, cardiovascular system protection, and homeostasis \[[4](#CIT0004)\]. In addition, the occurrence and development of many tumors have been shown to be estrogen dependent \[[4](#CIT0004)\]. Increasingly, ESR (estrogen receptor) ligands are being designed, synthesized, and used to treat related diseases, and some have already been used clinically \[[5](#CIT0005)\]. As early as a few decades ago, it was reported that estrogen affects the autophagy of renal tubules \[[6](#CIT0006),[7](#CIT0007)\]. In the past 10 years, a number of studies have reported that ESR ligands affect autophagy-related proteins and morphologies in different tissues \[[8](#CIT0008)--[40](#CIT0040)\]. However, these reports are quite scattered ([Table 1](#T0001), [2](#T0002)). Some results, especially those regarding the modulatory effect on autophagy of 17β-estradiol (E2), the major endogenous estrogen in mammals, seem inconsistent ([Table 1](#T0001)) \[[8](#CIT0008)--[20](#CIT0020)\]. In view of the importance of the crosstalk between estrogen signaling and autophagy, this review summarizes the ESR ligands reported to affect autophagy (characteristic autophagy proteins and key morphologies). In addition, tissue and subcellular distribution of the ESRs, autophagy-targeted TFs, miRNAs, and histone modifications are discussed as well. Finally, we examine the potential crosstalk between estrogen signaling and the autophagy pathway and summarize the molecular mechanisms involved in the regulation of autophagy by estrogen. We hope this will not only enrich our understanding of the known estrogenic regulation, but also promote more insight into the molecular mechanisms of estrogen's action on autophagy.10.1080/15548627.2018.1520549-T0001Table 1.The regulation of E2 on autophagy.LigandActionDiseaseCell Line or AnimalTissueDoseEffector proteinsAutophagy morphologyRefE2InduceBreast cancerMCF-7breast10 nMMAP1LC3-II/MAP1LC3-I, SQSTM1, BCL2, ESR1↓autophagosome\[[8](#CIT0008)\]Hypoxia-induced pulmonary hypertensionPAEClung1, 10 nMMAP1LC3-II, ER-independentNA\[[9](#CIT0009)\]Male Sprague-Dawley rats75 µg/kg/dayMAP1LC3-II, MAP1LC3-I, IFI27, MAPK1↓NA\[[10](#CIT0010)\]NephrotoxicitymProx24proximal renal tubule0.2 mg/kg/dayMAP1LC3-II/MAP1LC3-I, SQSTM1, SOCS3, STAT3↓, MAPK1autophagosome\[[11](#CIT0011)\]OsteoporosisMC3T3-E1bone10 nMMAP1LC3-II/MAP1LC3-I, BCL2, BECN1, AKT1, ULK1NA\[[12](#CIT0012)\]Ovarian cancerSkov-3, Ovcar-3(HTB-161), A2780 (ESR1^−^), A2780CP (ESR1^−^)ovary10 μMMAP1LC3B-II, MAP1LC3B-I↓, AKT1↓BECN1↓, GAPDH↓acidic vesicular organelles\[[13](#CIT0013)\]Parkinson disease/CNS1 mg/kg/dayMAP1LC3-II, MAPK1autolysosomes/\
autophagosomes\[[14](#CIT0014)\]Renal cell carcinomaRCC cell lineskidney7, 28 µMMAP1LC3B-II, MAP1LC3B-I↓, SQSTM1autophagosome\[[15](#CIT0015)\]Testicular germ cell tumorsTCAM2testis1, 10, 100 nMBECN1, AMBRA1, PIK3C3, UVRAG, PIK3CA-III, ESR2↓, AKT1↓autophagic vesicles\[[16](#CIT0016)\]restrict\
(prevent induced autophagy)Heart diseaseH9c2 cellsheart10 nMMAP1LC3-II↓, MAP1LC3-I, ESR2, AKT1, BNIP3NA\[[17](#CIT0017)\]Myocardial injurycardiomyocytesheart10 nMMAP1LC3-II/MAP1LC3-I, ATG5↓, BECN1↓NA\[[18](#CIT0018)\]Spinal cord injuryPC12adrenal medulla20 nMMAP1LC3-II↓, MAP1LC3-I, SQSTM1, BECN1↓, ATG5↓, ATG7↓NA\[[19](#CIT0019)\]Ovariectomy/proximal tibias10 µg/kg/dayMAP1LC3-II↓, MAP1LC3-I↓, SQSTM1, ATG5↓, BECN1↓acidic vesicular\[[20](#CIT0020)\][^1] 10.1080/15548627.2018.1520549-T0002Table 2.The regulation of autophagy by ESR ligands [^a.^]{.ul}DiseaseTissueCell lineLigandTypeDoseEffector proteinsAutophagy morphologyRefBreast cancerbreastMCF-7FulvER antagonist1 μMMAP1LC3-II, MAP1LC3-I, BCL2↓, BECN1, MAPK/ERK, AKT1↓autophagosomes\[[21](#CIT0021),[22](#CIT0022)\]T47D, MCF-7, BT-474, tam4-OH TAMER antagonist0.5, 1, 5 μMMAP1LC3-II, NO, MAPK1, PLIN2, BCL2↓autophagosomes, lysosomes/autolysosomes increased\[[23](#CIT0023),[24](#CIT0024)\]MCF-7, MCF-7 tamR, LCC2, MDA-MB-231TAMSERM1, 3, 5 μMMAP1LC3-II/MAP1LC3-I, SQSTM1, BECN1, MAPK1/3, BAX-BCL2, ATG12--ATG5autophagic vacuoles, increases autophagosomes\
/MDC-labeled vesicles\[[21](#CIT0021),[22](#CIT0022),[25](#CIT0025)--[28](#CIT0028)\]MCF-7raloxifeneSERM10 μMMAP1LC3-II, BECN1, ATG12--ATG5 conjugatesautophagic flux, autophagic vacuoles\[[29](#CIT0029)\]MCF-7/LCC1, MCF-7/LCC9, MCF-7CLL17\
WAY-20,070ESR2 agonist10 nMMAP1LC3-II/MAP1LC3-I, BCL2↓, ESR1↓NA\[[30](#CIT0030)\]MCF-7, (CCD1059sKgenisteinGPER1 agonist100 μMMAP1LC3/MAP1LC3B, BAX-BCL2autophagosome\[[31](#CIT0031)\]MCF-7, MCF10a,\
MDA-MB-231resveratrolmixed ER agonist/antagonist100 μMMAP1LC3-II↓, MAP1LC3-I↓, SQSTM1prevents rapamycin-induced upregulation of autophagy\[[32](#CIT0032)\]Diabetic cardiac function lheartH9c2resveratrolmixed ER agonist/antagonist100 μMestrogen-regulated genesinduces RICTOR and activates AKT1\[[33](#CIT0033)\]Pituitary tumorpituitary glandGH3resveratrolmixed ER agonist/antagonist25, 50 μMMAP1LC3-II/MAP1LC3-I, BECN1, BCL2↓,NA\[[34](#CIT0034)\]GlioblastomaglioblastomaU87, X1016, JX6TAMSERM9, 12 μMMAP1LC3-II, MAP1LC3-I,\
ATG5↓induces autophagic vacuole formation\[[35](#CIT0035)\]Oral squamous cell carcinomamouthSCC4, SCC9, HSC-3G15GPER1 antagonist0--20 μMMAP1LC3B-II, MAP1LC3B-I, BCL2↓, AKT1↓, MAPK1↓, GPER1↓autophagosome\[[36](#CIT0036)\]OsteosarcomaboneMG632-MEGPER1 agonist10 μMMAP1LC3-II/MAP1LC3-INA\[[37](#CIT0037)\]Ovarian cancerovaryPEO1, BG-1, SKOV-3RFulvER antagonist1 μMMAP1LC3-II, MAP1LC3-I, IFI27, PARP1, ESR1↓induces autophagy (not alone)\[[38](#CIT0038),[39](#CIT0039)\]ToxoplasmosisbreastMCF-7TAMSERM5, 10 μMMAP1LC3-II, MAP1LC3-INA\[[40](#CIT0040)\][^2]

Regulation of E2 on autophagy {#S0002}
=============================

As early as the 1970s, an association between castration and altered ultrastructural patterns of autophagosomes and lysosomes in different tissues was reported \[[6](#CIT0006),[7](#CIT0007)\]. In early reports, castration leads to a higher rate of autophagy with an increased number of lysosomes and degrading organelles, which suggested for the first time that the systemic deprivation of steroid sex hormones could be linked to autophagy \[[6](#CIT0006),[7](#CIT0007)\]. However, both the molecular mechanisms and signaling mediators of autophagy were poorly known then. In recent years, increasing research has shown that autophagy is involved in the effects of estrogen on various diseases ([Table 1](#T0001)).

The process of autophagy requires the coordination of numerous proteins. To determine whether autophagy is inhibited or promoted not only depends on the single index of biomarker proteins such as MAP1LC3, but also on changes of autophagy flux, autophagy substrates, and key autophagy morphology \[[41](#CIT0041)\]. For example, chloroquine inhibits autophagy by blocking the fusion of lysosomes with autophagosomes, resulting in the accumulation of MAP1LC3-II and autophagosomes. Therefore, some of the actions on autophagy shown in [Table 1](#T0001) need further confirmation. However, it is clear that E2 has multiple effects on autophagy. In many cases, E2 plays a role in promoting autophagy \[[8](#CIT0008)--[16](#CIT0016)\], but at other times, when cellular autophagy has been stimulated by hypoxia, lipopolysaccharides (LPS), spinal cord injury, or ovariectomy, E2 shows a restrictive effect on gene expression of some autophagy proteins \[[17](#CIT0017)--[20](#CIT0020)\]. Similar phenomena have also been observed for resveratrol, which can prevent the upregulation of autophagy induced by rapamycin ([Table 2](#T0002)).

Both endogenous and exogenous ESR ligands perform biological functions with specific receptors, classical nuclear receptors (ESR1 and ESR2), and a membrane receptor, GPER1 (G protein-coupled estrogen receptor 1) \[[5](#CIT0005)\]. In the classical pathway, activated ESRs undergo conformational changes after binding with estrogen, release from the heat shock proteins (HSPs), and then transfer to the nucleus and form homologous or heterologous dimers. In the nucleus, ESRs interact with the estrogen responsive element (ERE) and regulate the expression of target genes, including some autophagy-related genes, directly or indirectly through TFs \[[42](#CIT0042)\]. Different from ESRs, GPER1 in the cytoplasm mainly takes part in the rapid response of cells to estrogen \[[42](#CIT0042)\].

Based on the classical pathway, ESR antagonists such as tamoxifen, raloxifene, and fulvestrant have been designed, synthesized, and used in clinical treatment of ESR-positive breast cancer \[[5](#CIT0005)\]. However, these ESR antagonists are GPER1 agonists and are able to induce rapid activation of protein kinases, cAMP production, and gene transcription via GPER1 \[[42](#CIT0042)\]. Some specific regulators targeting GPER1 have been developed but have not yet been used in the clinic. Unexpectedly, there is a slight difference between their effects on autophagy ([Table 2](#T0002)).

ESR distribution in organs and subcellular locations {#S0003}
====================================================

As shown in [Figure 1](#F0001), compared to ESRs, GPER1 is more widely expressed in human tissues. GPER1 is predominately expressed in the thyroid gland, skeletal muscle, adrenal gland, and kidney \[[43](#CIT0043)\]. In some organs, both ESR1 and ESR2 are expressed with GPER1 \[[44](#CIT0044)\], whereas in others, only one subtype of ESR is mainly expressed. It is worth mentioning that only ESR2 has ever been reported to be expressed in the stomach \[[45](#CIT0045)\].10.1080/15548627.2018.1520549-F0001Figure 1.Schematic view of ESR distribution in organs.

The expression of these receptors and their intracellular distribution are different in different cell types, and the effects of estrogen on their distribution are also different \[[46](#CIT0046)--[49](#CIT0049)\]. The subcellular localization of the receptors is closely related to their functions, and it changes in different cell types and physiological states. For example, upon binding with E2, ESRs located in endothelial cytosolic/nuclear and endothelial surface membranes are upregulated and activate NOS3 (nitric oxide synthase 3) via genomic and nongenomic pathways, respectively \[[50](#CIT0050)\]. The nitric oxide (NO) synthesized in this manner can suppress MTOR expression and induce autophagy \[[51](#CIT0051)\]. Mitochondrial ESRs (mtESRs) are expressed in many human cells including cardiac muscle, lens epithelium, and osteosarcoma, hepatoma, and breast cancer cells \[[52](#CIT0052)--[55](#CIT0055)\], and mediate the synthesis of mitochondrial respiratory chain proteins (MRCs) via induction with E2 \[[55](#CIT0055)--[57](#CIT0057)\]. The expression levels of mtESRs also increase with exposure to E2 \[[55](#CIT0055)--[57](#CIT0057)\]. However, the fate of mtESRs and their role during selective mitochondrial autophagy (mitophagy) is not yet clear. The subcellular localization of GPER1 might be related to different tumor characteristics. GPER1, being localized in the cytoplasm in breast cancer, is correlated with non-ductal carcinoma with better tissue differentiation and lower tumor grade, which is more common in luminal A and B breast cancers \[[58](#CIT0058)\]. In contrast, when GPER1 is localized in the nucleus, tumors are poorly differentiated or there is triple-negative breast cancer (TNBC), and the prognosis is even worse \[[58](#CIT0058)\]. Both ESR1 and GPER1 are distributed in lysosomes in an E2-dependent manner, revealing the existence of a lysosome-dependent degradation pathway for these receptors \[[59](#CIT0059),[60](#CIT0060)\]. Whether ESR1 and GPER1 distributed in lysosomes participate in autophagy upon fusion with autophagosomes, and their corresponding pathophysiological effects, is unclear.

In general, the intracellular translocation of these receptors remains controversial and appears to be frequently determined by estrogen, though they are clearly involved in the association between estrogen and autophagy ([Figure 2](#F0002)[)]{.ul}.10.1080/15548627.2018.1520549-F0002Figure 2.Action of ESR ligands on autophagy. Dashed lines indicate tissue type-dependent activation or inhibition; dotted lines indicate crosstalk between receptors.

TFs involved {#S0004}
============

As shown in [Figure 3](#F0003) and [Table 3](#T0003), all of the receptors that might mediate the regulation of estrogen on core autophagy proteins via TFs. These TFs are involved in the regulation of all autophagic processes, including autophagy induction, vesicle nucleation and elongation, and retrieval.10.1080/15548627.2018.1520549-T0003Table 3.Autophagy proteins regulated by E2 via TFs.Autophagy proteinsTFsEffect of TFs on AutophagyTissue or Cell LineRefReceptorEffect of E2 on TFsTissue or Cell LineRef**Regulation of autophagy induction**ULK1CEBPBEnhanceMouse liver\[[61](#CIT0061)\]ESR1PRKCA enhances CEBPB by MAPK14HL-60\[[62](#CIT0062)\]PRKCA and ESR1 are inversely relatedBreast cancer\[[63](#CIT0063)\]GPER1E2 activates GPER1-cAMP-PRKA-CREBMCF-7\[[144](#CIT0144)\]CREB controls CEBPB by TATA boxRat liver\[[65](#CIT0065)\]FOXO3EnhanceMouse skeletal muscle\[[68](#CIT0068)\]ESR1E2 enhances FOXO3MCF-7\[[70](#CIT0070)\]GPER1E2 inactivates FOXO3MCF-7\[[71](#CIT0071)\]TP53EnhanceHuman HCT116 cells\[[72](#CIT0072)\]ESR1ESR1 represses TP53-mediated transcriptionMCF-7\[[73](#CIT0073)\]ESR2ESR2 antagonizes ESR1-TP53-mediated transcriptional regulationMCF-7\[[74](#CIT0074)\]ZKSCAN3SuppressHuman HeLa cells\[[145](#CIT0145)\]ESR1ESR1 is inversely related to PRKCBreast cancer\[[63](#CIT0063)\]PRKC inactivates ZKSCAN3 by MAPK14Mouse\[[77](#CIT0077)\]**Vesicle nucleation** ATG14FOXO3EnhanceMouse liver\[[66](#CIT0066)\]ESR1E2 enhances FOXO3MCF-7\[[70](#CIT0070)\]GPER1Estrogen inactivates FOXO3MCF-7\[[71](#CIT0071)\]BCL2NFKB1EnhanceRat hippocampal neurons\[[78](#CIT0078)\]ESR1ESR1 inhibits NFKB1 activityMCF-7, HeLa, HEK293, HepG2\[[82](#CIT0082)\]ESR2ESR2 inhibits NFKB1 activityHeLa, U937, HCASMC, COV434.\[[82](#CIT0082)\]GPER1Activation of GPER1 decreases the transcriptional activities of NFKB1MDA-MB-231\[[83](#CIT0083)\]TFEBEnhanceMouse liver\[[87](#CIT0087)\]ESR1MTORC1 inhibits TFEBHeLa\[[88](#CIT0088),[89](#CIT0089)\]ESR2(p)-MTORC1 expression is mainly related to ERMCF-7\[[91](#CIT0091)\]STAT3SuppressB cell lymphoma\[[84](#CIT0084)\]ESR1ESR1 increases STAT3 transactivationMCF-7\[[86](#CIT0086)\]GPER1GPER1 decreases STAT3MDA-MB-231\[[83](#CIT0083)\]TP53\
(TP63, TP73)SuppressHuman HCT116 cells\[[72](#CIT0072),[146](#CIT0146)\]ESR1ESR1 represses TP53-mediated transcriptionMCF-7\[[73](#CIT0073)\]ESR2ESR2 antagonizes ESR1-TP53-mediated transcriptional regulationMCF-7\[[74](#CIT0074)\]BECN1FOXO3EnhanceMouse skeletal muscle\[[68](#CIT0068),[147](#CIT0147)\]ESR1E2 enhances FOXO3MCF-7\[[70](#CIT0070)\]GPER1E2 inactivates FOXO3MCF-7\[[71](#CIT0071)\]JUNEnhanceHuman cancer cells CNE2 and Hep3B\[[92](#CIT0092)\]ESR1E2 induces the MAPK1/3, JUN, and MAPK14-dependent mitochondrial apoptotic pathwayMouse spermatocyte-derived cell GC-2\[[94](#CIT0094)\]GPER1MCF-7\[[95](#CIT0095)\]NFKB1EnhanceHuman T-cells\[[79](#CIT0079)\]ESR1ESR1 inhibits NFKB1MCF-7, HeLa, HEK293, HepG2\[[82](#CIT0082)\]ESR2ESR2 inhibits NFKB1HeLa, U937, HCASMC, COV434.\[[82](#CIT0082)\]GPER1GPER1 decreases NFKB1MDA-MB-231\[[83](#CIT0083)\]PIK3C3FOXO3EnhanceMouse skeletal muscle\[[67](#CIT0067)\]ESR1E2 enhances FOXO3MCF-7\[[70](#CIT0070)\]GPER1E2 inactivates FOXO3MCF-7\[[71](#CIT0071)\]UVRAGTP53EnhanceHuman HCT116 cells\[[72](#CIT0072)\]ESR1ESR1 represses TP53-mediated transcriptionMCF-7\[[73](#CIT0073)\]ESR2ESR2 antagonizes ESR1-TP53-mediated transcriptional regulationMCF-7\[[74](#CIT0074)\]TFEBEnhanceMouse liver\[[87](#CIT0087)\]ESR1MTORC1 inhibits TFEBHeLa\[[88](#CIT0088),[89](#CIT0089)\](p)-MTORC1 expression is mainly related to ERMCF-7\[[91](#CIT0091)\]**Vesicle elongation**ATG4FOXO3EnhanceMouse skeletal muscle\[[147](#CIT0147)\]ESR1E2 enhances FOXO3MCF-7\[[70](#CIT0070)\]GPER1E2 inactivates FOXO3MCF-7\[[71](#CIT0071)\]TFEBEnhanceMouse liver\[[87](#CIT0087)\]ESR1MTORC1 inhibits TFEBHeLa\[[88](#CIT0088),[89](#CIT0089)\](p)-MTORC1 expression is mainly related to ERMCF-7\[[91](#CIT0091)\]TP53EnhanceHuman HCT116 cells\[[72](#CIT0072)\]ESR1ESR1 represses TP53-mediated transcriptionMCF-7\[[73](#CIT0073)\]ESR2ESR2 antagonizes ESR1-TP53-mediated transcriptional regulationMCF-7\[[74](#CIT0074)\]ATG7TP53EnhanceHuman HCT116 cells\[[72](#CIT0072)\]ESR1ESR1 represses TP53-mediated transcriptionMCF-7\[[73](#CIT0073)\]ESR2ESR2 antagonizes ESR1-TP53-mediated transcriptional regulationMCF-7\[[74](#CIT0074)\]ATG10TP53EnhanceHuman HCT116 cells\[[72](#CIT0072)\]ESR1,ESR1 represses TP53-mediated transcriptionMCF-7\[[73](#CIT0073)\]ESR2ESR2 antagonizes ESR1-TP53-mediated transcriptional regulationMCF-7\[[74](#CIT0074)\]ATG12FOXO3EnhanceMouse skeletal muscle\[[147](#CIT0147)\]ESR1E2 enhances FOXO3MCF-7\[[70](#CIT0070)\]GPER1E2 inactivates FOXO3MCF-7\[[71](#CIT0071)\]BNIP3CEBPBEnhanceMouse liver\[[61](#CIT0061)\]ESR1PRKCA enhances CEBPB by MAPK14HL-60\[[62](#CIT0062)\]PRKCA and ESR1 are inversely relatedBreast cancer\[[63](#CIT0063)\]GPER1E2 activates GPER1-cAMP-PRKA-CREBMCF-7\[[144](#CIT0144)\]CREB controls CEBPB by TATA boxRat liver\[[65](#CIT0065)\]FOXO3EnhanceMouse skeletal and heart muscle\[[67](#CIT0067),[69](#CIT0069),[147](#CIT0147)\]ESR1E2 enhances FOXO3 by ESR1MCF-7\[[70](#CIT0070)\]GPER1Estrogen mediates inactivation of FOXO3 by GPER1MCF-7\[[71](#CIT0071)\]NFKB1SuppressHuman pancreatic cancer cells\[[80](#CIT0080)\]ESR1ESR1 inhibits NFKB1MCF-7, HeLa, HEK293, HepG2\[[82](#CIT0082)\]ESR2ESR2 inhibits NFKB1HeLa, U937, HCASMC, COV434.\[[82](#CIT0082)\]GPER1GPER1 decreases NFKB1MDA-MB-231\[[83](#CIT0083)\]HIF1AEnhanceHuman HEK293 cells\[[96](#CIT0096)\]ESR1ESR1 directly upregulates HIF1AMCF-7\[[99](#CIT0099)\]ESR2ESR2 inhibits activity of HIF1AHEK293\[[97](#CIT0097)\]GPER1GPER1 upregulates HIF1AHUVEC\[[98](#CIT0098)\]GPER1 inhibits HIF1AMDA-MB-231\[[83](#CIT0083)\]STAT3SuppressHuman U87 cells\[[85](#CIT0085)\]ESR1ESR1 increases STAT3 transactivationMCF-7\[[86](#CIT0086)\]GPER1GPER1 decreases STAT3MDA-MB-231\[[83](#CIT0083)\]MAP1LC3CEBPBEnhanceMouse liver\[[61](#CIT0061)\]ESR1PRKCA enhance CEBPB by MAPK14HL-60\[[62](#CIT0062)\]PRKCA and ESR1 is inversely relatedBreast cancer\[[63](#CIT0063)\]GPER1E2 activates GPER1-cAMP-PRKA-CREBMCF-7\[[144](#CIT0144)\]CREB controls CEBPB by TATA boxRat liver\[[65](#CIT0065)\]FOXO3EnhanceMouse skeletal and heart muscle\[[67](#CIT0067)--[69](#CIT0069)\]ESR1E2 enhances FOXO3MCF-7\[[70](#CIT0070)\]GPER1E2 inactivates FOXO3MCF-7\[[71](#CIT0071)\]TFEBEnhanceMouse liver\[[87](#CIT0087)\]ESR1MTORC1 inhibits TFEBHeLa\[[88](#CIT0088),[89](#CIT0089)\](p)-MTORC1 expression is mainly related to ERMCF-7\[[91](#CIT0091)\]JUNEnhanceHuman nasopharyngeal carcinoma cells\[[93](#CIT0093)\]ESR1E2 induces the MAPK1/3, JUN, and MAPK14-dependent mitochondrial apoptotic pathwayMouse spermatocyte-derived cell GC-2\[[94](#CIT0094)\]GPER1MCF-7\[[95](#CIT0095)\]ZKSCAN3SuppressHuman HeLa cells\[[145](#CIT0145)\]ESR1ESR1 is inversely related to PRKCBreast cancer\[[63](#CIT0063)\]PRKC inactivates ZKSCAN3 by MAPK14Mouse\[[77](#CIT0077)\]SQSTM1CTNNB1/β-cateninSuppressHuman HT29 cells\[[136](#CIT0136)\]ESR1There is functional interaction between CTNNB1 and ESR1MCF-7, HCT116 cells, SW480, *Drosophila* eye\[[148](#CIT0148)\]NFKB1EnhanceHuman IMR90 and A549 cells\[[81](#CIT0081)\]ESR1ESR1 inhibits NFKB1MCF-7, HeLa, HEK293, HepG2\[[82](#CIT0082)\]ESR2ESR2 inhibits NFKB1HeLa, U937, HCASMC, COV434.\[[82](#CIT0082)\]GPER1GPER1 decreases activity of NFKB1MDA-MB-231\[[83](#CIT0083)\]TFEBEnhanceMouse liver\[[87](#CIT0087)\]ESR1MTORC1 inhibits TFEBHeLa\[[88](#CIT0088),[89](#CIT0089)\](p)-MTORC1 expression is mainly related to ERMCF-7\[[91](#CIT0091)\]**Retrieval**ATG2TP53EnhanceHuman HCT116 cells\[[72](#CIT0072)\]ESR1ESR1 represses TP53-mediated transcriptionMCF-7\[[73](#CIT0073)\]ESR2ESR2 antagonizes ESR1-TP53-mediated transcriptional regulationMCF-7\[[74](#CIT0074)\]ATG9TFEBEnhanceMouse liver\[[87](#CIT0087)\]ESR1MTORC1 inhibits TFEBHeLa\[[88](#CIT0088),[89](#CIT0089)\](p)-MTORC1 expression is mainly related to ERMCF-7\[[91](#CIT0091)\]WIPI2TFEBEnhanceMouse liver\[[87](#CIT0087)\]ESR1MTORC1 inhibits TFEBHeLa\[[88](#CIT0088),[89](#CIT0089)\](p)-MTORC1 expression is mainly related to ERMCF-7\[[91](#CIT0091)\]ZKSCAN3SuppressHuman HeLa cells\[[145](#CIT0145)\]ESR1ESR1 is inversely related to PRKCBreast cancer\[[63](#CIT0063)\]PRKC inactivates ZKSCAN3 by MAPK14Mouse\[[77](#CIT0077)\][^3] 10.1080/15548627.2018.1520549-F0003Figure 3.Regulation of E2 on core autophagy proteins via TFs. JUN, subunit of AP-1; TP53, tumor protein p53.

CEBPB {#S0004-S2001}
-----

CEBPB links autophagy to the biological clock and maintains nutrient homeostasis by stimulating autophagic gene expression \[[61](#CIT0061)\]. The increase of nuclear CEBPB protein is dependent on MAPK14. The phosphorylation of MAPK14 is in turn dependent on PLA2G1B (phospholipase A2 group IB), PRKC/PKC activation, and oxidative stress \[[62](#CIT0062)\]. Expression levels of ESRs and PRKCA are inversely related \[[63](#CIT0063)\]. CREBBP/CREB (CREB binding protein) controls CEBPB expression by interacting with 2 sites near the TATA box \[[64](#CIT0064)\]. Recent research has shown that the breast tumor cell-activated phosphoinositide 3-kinase-AKT1 signaling pathway induces cytoplasmic GPER1 translocation of carcinoma-associated fibroblasts in an XPO1 (exportin 1)-dependent pattern, and leads to the activation of the estrogen-GPER1-cAMP-PRKA/PKA-CREB signaling axis that triggers the aerobic glycolysis switch in carcinoma-associated fibroblasts \[[65](#CIT0065)\].

FOXO3 {#S0004-S2002}
-----

The *Atg14* gene is a direct target of FOXOs, and FOXOs positively regulate *Atg14* gene expression \[[66](#CIT0066)\]. In skeletal muscle, both the ubiquitin-proteasomal and autophagic-lysosomal pathways, the 2 major systems of protein breakdown, are under control of FOXO3. BNIP3 appears to mediate the effect of FOXO3 on autophagy \[[67](#CIT0067)\]. The activation of FOXO3 by PRKAA2 (protein kinase AMP-associated catalytic subunit alpha 2) induces the expression of MAP1LC3-II, ATG8, BECN1, and BNIP3 in mouse skeletal muscle \[[67](#CIT0067),[68](#CIT0068)\]. Constitutive activation of FOXO3 induces MAP1LC3-II and BNIP3 expression and leads to reversible heart atrophy in active *Foxo3* transgene mice by constitutive tetracycline regulation \[[69](#CIT0069)\]. E2 strongly enhances the effects of FOXO3 via ESR1 \[[70](#CIT0070)\]. In addition, estrogen mediates the inactivation of FOXO3 by GPER1 \[[71](#CIT0071)\]. FOXO3 proteins in human and mouse have the same AKT1 phosphorylation sites and similar regulatory properties \[[71](#CIT0071)\].

TP53 {#S0004-S2003}
----

TP53 is present in both the nucleus and cytoplasm, and its regulation in autophagy depends on its subcellular localization. The target autophagy genes of TP53 include *ULK1, ULK2, ATG2B, ATG4A, ATG4C, ATG7, ATG10, VMP1* (vacuole membrane protein 1), and *UVRAG* \[[72](#CIT0072)\]. Initially, ESR1 was reported to be a suppressor of TP53 that can recruit nuclear receptor co-repressors (NCOR1 and NCOR2) and HDAC1 (histone deacetylase 1) \[[73](#CIT0073)\]. However, recent research has shown that ESR2 can attenuate the crosstalk between ESR1 and TP53 by reducing the recruitment of both NCOR1 and NCOR2 by ESR1. ESR2 antagonizes ESR1-TP53-mediated transcriptional regulation by reducing ESR1-TP53 binding via physical interaction \[[74](#CIT0074)\]. In addition, the *MDM2* proto-oncogene, which is both a TP53 target gene and a negative feedback regulator of TP53, has bidirectional effects on ESR1 by direct interaction \[[75](#CIT0075)\].

ZKSCAN3 {#S0004-S2004}
-------

ZKSCAN3 and TFEB regulate lysosomal biogenesis and autophagy in an opposing manner \[[76](#CIT0076)\]. ZKSCAN3 is a repressor of several autophagy-related genes, including *MAP1LC3* and *WIPI2* (human homologs of yeast Atg18). WIPI2 has a positive role in the cycling of ATG9. ZKSCAN3 and TFEB are regulated in an opposing manner \[[76](#CIT0076)\]. For instance, PRKC leads to reduced phosphorylation, nuclear translocation, and activation of TFEB by inactivating GSK3B with a MTORC1-independent mechanism; however, PRKC activates MAPK8/JUN NH~2~-terminal kinase (mitogen-activated protein kinase 8) and MAPK14, which phosphorylate ZKSCAN3, leading to its translocation and inactivation. ZKSCAN3 phosphorylation at Thr153 by MAPK9 or MAPK14 is required for ZKSCAN3 cytoplasmic translocation and promotes lysosome biogenesis \[[77](#CIT0077)\]. The expression levels of ESRs and PRKC are inversely related \[[63](#CIT0063)\].

NFKB1 {#S0004-S2005}
-----

NFKB1 upregulates the expression of both BCL2 and BECN1 \[[78](#CIT0078),[79](#CIT0079)\]. However, NFKB1 silences *Bnip3* gene transcription by competing with E2F1 (E2F transcription factor 1) for binding to the *Bnip3* promoter \[[80](#CIT0080)\]. The ubiquitin-binding protein SQSTM1 is required for RAS-induced NFKB1 activation in human tumors \[[81](#CIT0081)\]. ESRs mediate the inhibition of NFKB1 activity at several levels \[[82](#CIT0082)\]. Activation of GPER1 by the specific agonist G-1 leads to significant inhibition of the phosphorylation, nuclear localization, and transcriptional activities of NFKB1 \[[83](#CIT0083)\]. Both IL6 (interleukin 6) and VEGFA (vascular endothelial growth factor A) are inhibited accordingly \[[83](#CIT0083)\].

STAT3 {#S0004-S2006}
-----

Functional crosstalk between BCL2, RAC1, and activated STAT3 exists and promotes a permissive redox milieu for cell survival \[[84](#CIT0084)\]. STAT3 signaling events occur downstream of MMP14/MT1-MMP (matrix metallopeptidase 14). Gene silencing of *MMP14* and *STAT3* abrogates both STAT3 phosphorylation and BNIP3 expression \[[85](#CIT0085)\]. Activation of GPER1 inhibits HIF1A and STAT3 signals in TNBC cells \[[83](#CIT0083)\]. Upon LEP (leptin) treatment, ESR1 increases the transactivation and target gene expression of *STAT3* by direct binding. In addition, the enhancement of LEP-mediated activation of STAT3 is independent of ESR1 ligands \[[86](#CIT0086)\].

TFEB {#S0004-S2007}
----

As a master regulator of lysosomal biogenesis, TFEB promotes the transcription of several lysosomal genes by directly binding to their promoters. Autophagy-related genes *Map1lc3, Sqstm1*, and *Atg9* are also upregulated by TFEB \[[76](#CIT0076),[87](#CIT0087)\]. Under well-nourished conditions, MTORC1 inhibits TFEB by its post-translational modification of phosphorylation. In contrast, under starvation conditions, lysosomal disruption and pharmacological inhibition of MTORC1 activates TFEB \[[88](#CIT0088),[89](#CIT0089)\]. Upon estrogen stimulation, ESR1 binds to RPTOR (regulatory associated protein of MTOR complex 1) \[[90](#CIT0090)\]. The MTOR kinase can phosphorylate Ser104/106 of ESR1 and promote the transcription of ER target genes \[[90](#CIT0090),[91](#CIT0091)\].

JUN {#S0004-S2008}
---

JUN is involved in the regulation of both *BECN1* and *MAP1LC3* transcription \[[92](#CIT0092),[93](#CIT0093)\]. In ESR- or GPER1-positive GC-2 cells, E2 induces the MAPK1/3, JUN, and MAPK14-dependent mitochondrial apoptotic pathway \[[94](#CIT0094)\]. In ESR-negative GPER1 or CYP19A1/aromatase-positive SKBR3 cells, tamoxifen acts as a GPER1 agonist and recruits the FOS-JUN complex to AP-1-responsive elements that are located within the *CYP19A1/aromatase* promoter \[[95](#CIT0095)\].

HIF1A {#S0004-S2009}
-----

The expression of BNIP3, BECN1, and ATG5 required for selective mitochondrial autophagy depends on HIF1A \[[96](#CIT0096)\]. ESR2 inhibits HIF1A activity by decreasing the binding of HIF1A to the promoter of the *VEGFA* gene, which attenuates *VEGFA* transcription induced by hypoxia \[[97](#CIT0097)\]. Activation of GPER1 by both E2 and G-1 increases VEGFA via upregulation of HIF1A via the GPER1-EGFR-MAPK1-FOS signaling pathway \[[98](#CIT0098)\]. The *HIF1A* gene itself contains an estrogen response element, and its expression is directly regulated by ESR1 \[[99](#CIT0099)\].

MiRNAs involved {#S0005}
===============

In addition to the transcription factors listed above, E2 can regulate the expression of some autophagy-related proteins by suppressing or stimulating miRNA expression.

MIR214 {#S0005-S2001}
------

Estrogen treatment downregulates the *MIR214* family \[[100](#CIT0100)\]. *MIR214* directly targets mitochondrial uncoupling proteins (UCPs) \[[101](#CIT0101)\]. UCPs are members of the larger family of mitochondrial anion carrier proteins (MACPs), and UCP2 is involved in uncoupling oxidative phosphorylation and facilitating energy dissipation as heat \[[102](#CIT0102)\]. UCP2 overexpression not only decreases nonspecific destructive intracellular reactive oxygen species (ROS), but also induces autophagy and endocrine resistance by the phosphorylation of AKT1 and MTOR \[[21](#CIT0021)\].

MIR21 {#S0005-S2002}
-----

Regulation of *MIR21* transcription by E2 varies depending on experimental conditions, cell line, and control genes used in the analysis. In HepG2 human hepatoma cells, E2 inhibits *MIR21* expression via ESR1 \[[103](#CIT0103)\]. In MCF-7 cells, *MIR21* is upregulated by the ESR2 selective ligand diarylpropionitrile (DPN) \[[104](#CIT0104)\]. In systemic lupus erythematosus, estrogen-regulated STAT1 activates and promotes TLR8 expression via *MIR21* \[[105](#CIT0105)\]. Both the expression and functional loss of STAT1 are related to the development of mammary adenocarcinomas \[[106](#CIT0106)\]. STAT1 suppresses ATG12 and BECN1 \[[107](#CIT0107)\]. *MIR21* also targets *BCL2* mRNA in rat and human beta cells \[[108](#CIT0108)\].

Long noncoding RNA *HOTAIR* {#S0005-S2003}
---------------------------

E2-GPER1 induces HOTAIR through the suppression of *MIR148A* \[[109](#CIT0109)\]. In hepatocellular carcinoma, HOTAIR activates autophagy by upregulating ATG3 and ATG7 \[[110](#CIT0110)\]. In endometrial cancer cells, HOTAIR regulates autophagy and contributes to cisplatin-induced resistance \[[110](#CIT0110)\]. In addition, BECN1, multidrug resistance (MDR), and ABCB1 (ATP binding cassette subfamily B member 1) are all regulated by HOTAIR \[[111](#CIT0111)\].

MIRLET7G {#S0005-S2004}
--------

In MCF-7 cells, E2 suppresses the expression of *MIRLET7G* in a time- and MAP2K/MEK-MAPK-dependent manner \[[104](#CIT0104)\]. *Mirlet7g* regulates autophagy in mouse granulosa cells by targeting IGF1R (insulin like growth factor 1 receptor) and downregulates AKT-MTOR \[[112](#CIT0112)\]. Direct regulation of *MIRLET7G* by E2 via ESR1 has been reported \[[104](#CIT0104),[113](#CIT0113)\].

In addition, *MIR30D* increases with hormone deprivation in MCF-7 cells. *MIR30D* regulates autophagy genes including *BECN1, ATG5, ATG12*, and *ATG2* \[[76](#CIT0076)\]. However, dextran-coated charcoal stripping to treat serum in the original report could eliminate many hormones from the serum, which leaves the effect of estrogens on *MIR30D* unclear \[[104](#CIT0104)\].

Histone modifications involved {#S0006}
==============================

Histones are the chief protein components of chromatin. Various posttranslational modifications on histones are mainly produced by histone-modifying enzyme complexes in a dynamic manner \[[76](#CIT0076)\]. These post-translational modifications, including acetylation and methylation, can influence the overall chromatin structure and have clear functional consequences \[[76](#CIT0076)\]. Acetylation is a modulator of the ligand-dependent gene regulatory activity of ESRs \[[114](#CIT0114)\]. Estrogen can interfere with the nuclear regulation of autophagy by regulating proteins in histone modifier complexes. Such regulation of histone modification by estrogen is likely to play a role in estrogen-dependent signaling pathways in a variety of estrogen target tissues in both normal and pathological states.

HDACs {#S0006-S2001}
-----

In skeletal muscle, HDAC1 and HDAC2 regulate autophagy by inducing autophagic gene expression and autophagosome formation. Loss of these HDACs leads to the accumulation of toxic autophagic intermediates in the myofibers of mice \[[115](#CIT0115)\]. In cardiomyocytes, HDAC inhibitors suppress autophagy. HDAC1 and HDAC2 are required for the autophagic response, and the overexpression of HDAC2 alone increases autophagy \[[116](#CIT0116)\]. E2 or dipropylnitrile and β-LGND2 (ESR2 agonists) comparably suppress HDAC2 production, phosphorylation, and the resulting prohypertrophic mRNA expression induced by angiotensin II \[[117](#CIT0117)\]. The expression of ESR1 can be reactivated by destabilization or reduction of the corepressor complex, formed by MTA1 (metastasis associated 1), IFI16 (interferon gamma inducible protein 16), and HDACs, on the *ESR1* promoter \[[118](#CIT0118)\].

HATs {#S0006-S2002}
----

Several HATs have ubiquitination-linked enzymatic activity. As a HAT, KAT2B (lysine acetyltransferase 2B) acetylates both histone and non-histone proteins and promotes autophagy by inhibiting the AKT1-MTOR signaling pathway \[[119](#CIT0119)\]. DNA binding and transactivation activities of ESR1 are enhanced by acetylation at lysines 266 and 268 by EP300, which can be reversed by native deacetylases such as SIRT1 (sirtuin 1) \[[114](#CIT0114)\]. KAT7, another HAT, promotes the degradation of ESR1 through ubiquitination in a proteasome-dependent manner. KAT7 knockdown promotes ESR1 expression \[[120](#CIT0120)\]. *In vitro*, E2 inhibits the E3 ubiquitin ligase activity of KAT7 on ESR1 \[[120](#CIT0120)\].

Post-translational status of histone H3 {#S0006-S2003}
---------------------------------------

ESR1 silences TP53-activated transcription by directing the assembly of SUV39H1/histone-lysine N-methyltransferase (suppressor of variegation 3--9 homolog 1) and histone H3 lys9 trimethylation (H3K9me3) at estrogen-repressed genes \[[74](#CIT0074)\]. ESR2 downregulates SUV39H1/H2 and releases the ESR1-induced transcriptional block by abrogating the repressive heterochromatin conformation of H3K9me3 \[[74](#CIT0074)\]. Furthermore, ESR2 stimulates the accumulation of trimethylated histone H3 lys4 (H3K4me3) and POLR2/RNA polymerase II on ESR1-repressed genes, which then induces the transcription of the repressed genes involved in TP53-based tumor suppression \[[74](#CIT0074)\].

Balancing acetylation at H4K16 {#S0006-S2004}
------------------------------

Dynamic histone modifications play a pivotal role in cell-regulatory events \[[121](#CIT0121)\]. The acetylation of histone H4 at lysine 16 (H4K16) can influence higher-order chromatin structure, which plays an important role in transcription \[[76](#CIT0076)\]. Acetylated H4K16 is a primary histone substrate of native deacetylase SIRT1 \[[76](#CIT0076)\]. In addition, SIRT1 has several non-histone targets, including ATG5, ATG7, MAP1LC3, FOXOs, E2F1, TP73, PPARGC1A (PPARG coactivator 1 alpha), NFKB1, and TP53, all of which are involved in the regulation of autophagy \[[76](#CIT0076)\]. In oxygen-glucose deprived neurons, estrogen promotes PRKAA2 activation through ESR1 \[[122](#CIT0122)\]. Estrogen increases SIRT1 expression and activation \[[123](#CIT0123)\]. In *sirt1*-knockout neurons, estrogen-induced PRKAA2 activation disappears, which prevents the neuroprotection of estrogen \[[122](#CIT0122)\].

Concluding remarks and future perspectives {#S0007}
==========================================

The modulation of estrogenic effects relating to autophagy could contribute to the development of potential strategies to treat numerous human diseases ([Table 1](#T0001), [2](#T0002)). To clarify the estrogenic function of autophagy between normal physiological and pathological conditions, including tumors, there have been several studies on the estrogenic regulation of autophagy in ESR-positive breast cancers \[[124](#CIT0124)--[128](#CIT0128)\]. Arguably, much of what is known has come from this area, reflecting the fact that breast cancer is the most common cancer in women, and 70% are treated with drugs that target ESR action. The roles of autophagy in cancer have been confounded by numerous laboratory studies showing that both the enhancement and inhibition of autophagy seem to improve cancer treatment outcomes \[[129](#CIT0129),[130](#CIT0130)\]. A similar situation is also seen in other diseases, such as clinically relevant murine models of ischemic stroke \[[131](#CIT0131)\]. Moreover, several clinical trials are already in place combining both autophagy inducers (rapamycin, everolimus) and autophagy inhibitors (chloroquine, 3-methyladenine) with endocrine therapies \[[132](#CIT0132),[133](#CIT0133)\]. Not all patients experience benefit, which further confuses and complicates our understanding of the main effects of autophagy in breast cancer.

Based on previously reported models \[[134](#CIT0134),[135](#CIT0135)\], a hypothetical model ([Figure 4](#F0004)) is presented here to help understand how the estrogenic regulation of autophagy affects cell fate. Autophagy is vital for intracellular quality control and homeostasis. Therefore, careful regulation of autophagy is very important because either excessive or insufficient autophagy can be destructive to cells \[[136](#CIT0136)\]. It has been proven that estrogen can delay the apoptosis of breast cancer cells via ESRs \[[137](#CIT0137)\]. For the treatment of estrogen-related cancer cells, estrogen needs to be antagonized, which might be because of the protective effect of estrogen on cell balance via regulation of autophagy as shown here.10.1080/15548627.2018.1520549-F0004Figure 4.Model of how estrogenic regulation of autophagy affects cell fate. E2 helps maintain moderate autophagy and cellular homeostasis. Both deficient and excessive autophagy are abnormal. Deficient autophagy can lead to unfolded protein response (UPR) stress, which may reestablish homeostasis through the induction of autophagy. However, the UPR can further lead to carcinogenesis. The proliferation of cancer may induce a status of hypoxia and starvation, both of which can induce autophagy. Here, if a new balance is achieved, cells still have a chance to survive, which is bad for the treatment of cancer. Only when excessive autophagy releases enough calcium from the endoplasmic reticulum to the cytoplasm can apoptosis be triggered. Furthermore, activated caspases will cleave BECN1 and turn off autophagy. Autophagy inducers may prevent carcinogenesis when autophagy in non-cancer cells is deficient, or they may promote excessive autophagy in cancer cells and lead to apoptosis. Autophagy inhibitors seem to block the survival of cancer cells during starvation; however, the inhibition of autophagy cannot persist. The persistent stimulation of UPR stress also promotes autophagy.

As shown in this review, upon stimulation with estrogen, most autophagy-related genes are under the regulation of more than one TF, and most TFs are under the regulation of 2 or 3 receptors of estrogen. In addition, estrogen can interfere with autophagy via nuclear regulation by histone modifications. Thus, there will always be opposing functional actions, which might occur between different receptors, receptors on TFs, TFs on autophagy genes, or even histone modifications on transcription. In addition to those mentioned above, such as ESR1 and ESR2 \[[74](#CIT0074)\], TFEB and ZKSCAN3 \[[76](#CIT0076)\], and TP53 and MDM2 \[[75](#CIT0075)\], need to be further explored in the future. The huge signaling network downstream of estrogen can promote autophagy and reduce overstimulated autophagy at the same time, which allows autophagy to be regulated by estrogen in a restricted range. Estrogen's mechanism of balancing autophagy is obviously more complicated than this. For instance, estrogen in the blood can cause negative feedback to reduce levels of hormones in the body. In addition to estrogen, other hormones, such as androgens, also play a role in autophagy \[[138](#CIT0138)\]. Some estrogen-regulated TFs and miRNAs can target ESRs, thereby forming another negative feedback loop to fine-tune estrogen-mediated cellular responses, including autophagy \[[104](#CIT0104),[139](#CIT0139)\].

Because autophagy is tightly controlled by estrogen ([Figure 5](#F0005)), it would make sense to determine the fluctuation range of autophagy corresponding to estrogenic regulation under various physiological and pathological conditions. This leads to a major problem for autophagy research -- autophagy is a dynamic process that is hard to assess in living organisms (especially humans) by existing methods *in vitro* \[[129](#CIT0129)\]. Considering the correlation between autophagy and cell substance balance, if we indirectly characterize autophagy by assessing the material and energy balance in cells instead of focusing solely on the process of autophagy itself, it will be easier to choose between autophagy inducers and inhibitors in the future. Of course, the optimal choice of markers remains to be determined. However, it is foreseeable that developing dynamic markers of cellular balance will be conducive to studying autophagy manipulation and clinical therapeutics.10.1080/15548627.2018.1520549-F0005Figure 5.Association between estrogen and autophagy. E2 balances the expression of core autophagy proteins through diverse transcription factors, miRNAs, and histone modifications via signaling pathways downstream of the receptors. The autophagic proteins controlled by E2 are involved in the entire process of autophagy. Lipids released by autophagy are the major source of cholesterol, the precursor of estrogen biosynthesis. E2 in the blood causes a negative feedback to reduce circulating levels of hormones. E2 activates NOS3 and initiates the synthesis of NO via membrane ESRs. NO induces autophagy by suppressing MTOR expression. In addition, some estrogen-regulated TFs and miRNAs can target ESRs. As the major mechanism for ESR degradation in eukaryotic cells, ESRs dissociate from complexes with HSPs upon binding of E2, are ubiquitinated by ubiquitin ligases (ULs), and are targeted for degradation. The fate of mtESRs and lysosomal ESR1 and GPER1 during autophagy is not yet clear. Ac, acetylation; GF, growth factor; HSPs, heat-shock proteins; HRAS, HRas proto-oncogene, GTPase; Me, methylation; RAF1, Raf-1 proto-oncogene, serine/threonine kinase; RTKs, receptor tyrosine kinases; SRC, SRC proto-oncogene, non-receptor tyrosine kinase; ULs, ubiquitin ligases.

So far, studies of estrogen function on autophagy have mainly focused on breast tissue, however there are still many issues that need to be clarified. Take for example the TFs: although the effects of estrogen on TFs have mostly focused on breast cancer cells, the effects of TFs on autophagy are rarely seen in breast cancer cells ([Table 3](#T0003)). In other tissues such as brain and bone, the role of autophagy has also been studied for its importance \[[140](#CIT0140),[141](#CIT0141)\]. With regard to estrogenic regulation of autophagy in these tissues, there are also some related studies ([Tables 1](#T0001) and [2](#T0002)). Except for the issues mentioned above for breast cancer, more issues need to be solved for the diseases of these tissues. Take for example gliomas: there have been no clinical studies combining both autophagy inducers and autophagy inhibitors with ESR ligands, though they all have independent clinical trials \[[142](#CIT0142),[143](#CIT0143)\]. The specificity of drug distribution in these tissues also need to be addressed \[[143](#CIT0143)\].

In addition, although GPER1 is more widely distributed in human tissues than ESRs and is expressed in TNBC cells and associated with drug resistance of ESR antagonists in endocrine therapy, GPER1 antagonists are very few and have not been developed to work in humans \[[5](#CIT0005)\]. Whether ESR1 and GPER1 distributed in lysosomes participate in autophagy upon fusion with autophagosomes, and the corresponding pathophysiological effects, are not clear. High levels of some autophagy biomarkers such as MAP1LC3, or autophagy morphologies such as autophagosomes triggered by the induction or accumulation caused by autophagy inhibition, need stricter distinction in future research. These directions might allow us to better understand the multiple associations between estrogen and autophagy, the pathogenic mechanisms of many estrogen-related diseases, and to design novel and efficacious therapeutics.
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[^1]: Abbreviations: AKT1/PKB, AKT serine/threonine kinase 1; AMBRA1, autophagy and beclin 1 regulator 1; ATG, autophagy related; BECN1, beclin 1; BNIP3, BCL2 interacting protein 3; CNS, central nervous system; E2, 17β-estradiol; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IFI27/p27, interferon alpha inducible protein 27; MAP1LC3/LC3, microtubule associated protein 1 light chain 3; MAPK1/ERK, mitogen-activated protein kinase 1; PAEC, pulmonary artery endothelial cells; PIK3C3/VPS34, phosphatidylinositol 3-kinase catalytic subunit type 3; PLIN2/ADRP, perilipin 2; SOCS3, suppressor of cytokine signaling 3; SQSTM1/p62, sequestosome 1; STAT, signal transducer and activator of transcription; ULK1, unc-51 like autophagy activating kinase 1; UVRAG, UV radiation resistance associated. ↓, genes are upregulated by E2 unless so marked, which indicates that E2 downregulates them.

[^2]: ^a^ Abbreviations: 2-ME, 2-methoxyestradiol; 4-OH TAM, 4-hydroxytamoxifen; BAX, BCL2 associated X, apoptosis regulator; BCL2, BCL2, apoptosis regulator; Fulv, fulvestrant; MTOR, mechanistic target of rapamycin kinase; MDC, monodansylcadaverine; RICTOR, RPTOR independent companion of MTOR complex 2; SERM, selective estrogen receptor modulator; TAM, tamoxifen. ↓, genes are upregulated by ESR ligands unless so marked, which indicates that ESR ligands downregulate them.

[^3]: Abbreviations: A549, human lung adenocarcinoma cells; CEBPB, CCAAT enhancer binding protein beta; COV434, Human ovarian granulosa tumor cells; CREBBP, CREB binding protein; FOXO3, forkhead box O3; GC-2, a mouse spermatocyte cell line; GCT, granulosa cell tumors; HCASMC, human coronary artery smooth muscle cells; HCT116, human colon carcinoma cells; HEK293, human embryonic kidney 293 cells; HepG2, a human liver cancer cell line; HIF1A, hypoxia inducible factor 1 subunit alpha; HL-60, human promyelocytic cells; HT29, human colorectal carcinoma cells; HUVEC, human umbilical vein endothelial cells; IMR90, normal human lung fibroblasts; MAPK9/JNK2, mitogen-activated protein kinase 9; MAPK14/p38, mitogen-activated protein kinase 14; MTORC1, mechanistic target of rapamycin kinase complex 1; NFKB1/NF-κB, nuclear factor kappa B subunit 1; PRKC/PKC, protein kinase C; SMCs, human coronary artery smooth muscle cells; STAT3, signal transducer and activator of transcription 3; SW480, a p53 double-mutant cell line; TFEB, transcription factor EB; U87, human primary glioblastoma cells; U937, human macrophagy cells; WIPI2, WD repeat domain, phosphoinositide interacting 2 (a homolog of yeast Atg18); ZKSCAN3, zinc finger with KRAB and SCAN domains 3.
